AI-enabled qualitative analysis of NTD funding

Evidano is an AI-powered qualitative data analysis platform that parses heterogeneous documents, extracts themes and co-occurrences, and secures sensitive data.

The PLoS review (published July 9, 2026) concluded that introducing a nondonated fixed-dose combination (FDC) of ivermectin/albendazole faces major supply and financing barriers in low- and lower-middle-income countries.

• 35 sources were reviewed and the paper cites an estimated ~1.5 billion people infected with STH.
• More than $15 million was invested to develop the FDC, and Ghana licensed the FDC in late 2025.
• Researchers should use targeted qualitative synthesis to align donors, manufacturers, and ministries on financing models, pooled procurement, and health-system integration.

This table summarizes the paper's key dates and metrics cited in the review and accompanying notes.

The paper synthesized peer-reviewed and gray literature, WHO SARA facility availability data, and World Bank health-expenditure indicators to examine three determinants of sustainable access: facility-level medicine availability, health financing patterns, and donation models.

• WHO SARA data showed some low-income countries reported 0% sustained availability of core essential medicines in facilities, with examples including Burundi, Burkina Faso, and Mali; the review also highlighted Haiti and Tanzania.
• Health financing analysis showed many African and Asian countries spend roughly half of aspirational targets on public health, with low-income countries relying heavily on external aid and out-of-pocket payments.
• The donation landscape analysis showed major manufacturers donate monotherapies at scale (GSK albendazole, J&J mebendazole, Merck ivermectin), and the review noted that no pooled global financing mechanism exists for NTD medicines, raising questions about whether the new FDC will be donated.

Follow these seven steps to reproduce the synthesis described in the PLoS review and this post.

Step 1: Collect documents; PLoS review, SARA extracts, World Bank indicators, donor statements, and 10–20 stakeholder interview transcripts.

Step 2: Import into Evidano and run language normalization and a dictionary (map terms like 'FDC', 'MDA', 'co-financing').

Step 3: Auto-generate an initial codebook from top themes and refine with 2–3 manual adjustments.

Step 4: Run thematic and frequency and cross-segment analyses (LIC vs LMIC vs UMIC).

Step 5: Create co-occurrence networks and a short evidence table linking claims to sources and dates.

Step 6: Draft a 2-page policy brief and a 5-slide stakeholder deck using exported quotes and visuals.

Step 7: Share a locked report with partners and track follow-up questions via AI chat over your documents in Evidano.

The PLoS review (published July 9, 2026) identifies a narrow window to re-engineer access models for NTD medicines as the new ivermectin/albendazole FDC reaches regulators.

For researchers and policy teams, a targeted qualitative analysis of funding narratives and procurement capacity will change the conversation from feasibility to actionable financing designs, using the checklist and workflows above.

Ready to test this workflow on your dossier? Try Evidano for free.

Ethics note: this post summarizes research and policy analysis; it is not clinical guidance.